Guidelines for avoiding risks resulting from discontinuation of nucleos(t)ide analogues in patients with chronic hepatitis B (2012)

Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B

“…We performed research funded by a Health and Labor Sciences Research Grant to investigate characteristics of the course after discontinuation of treatment, definition of hepatitis relapse and estimation of relapse rate . “Guidelines for avoiding risks resulting from discontinuation of NUCs 2012” is summarized based on the study results . The guidelines do not always recommend discontinuation of NUC.…”

“…6 "Guidelines for avoiding risks resulting from discontinuation of NUCs 2012" is summarized based on the study results. 7 The guidelines do not always recommend discontinuation of NUC. We determined them to be referred to if it is necessary to consider discontinuation of NUC due to various reasons.…”

JSH Guidelines for the Management of Hepatitis B Virus Infection

“…Based on the above results, the MHLW research group produced a report titled “Studies concerning efficacy of IFN therapy aimed at creation of treatment discontinuation standards and treatment discontinuation in NAs therapy for hepatitis B”, setting out policy regarding cessation of NA therapy . A summary is shown in Table .…”

“…208 Based on the above results, the MHLW research group produced a report titled "Studies concerning efficacy of IFN therapy aimed at creation of treatment discontinuation standards and treatment discontinuation in NAs therapy for hepatitis B", setting out policy regarding cessation of NA therapy. 209,210 A summary is shown in Table 14. To determine the criteria for therapy cessation, as shown below in Table 15, HBsAg and HBcrAg levels at therapy cessation were scored, the final score allocated to the following 3 categories of risk of relapse, and the success rate was predicted.…”

“…Even in cases of recurrence of hepatitis following cessation of entecavir therapy, retreatment with entecavir should be considered. The criteria for recurrence of hepatitis are HBV DNA levels ≥5.8 log copies/mL, or ALT levels ≥80 U/L …”